- Conditions
- Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization, Cystic Fibrosis
- Interventions
- AZLI, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 3 Months to 18 Years
- Enrollment
- 149 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 12
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • St. Petersburg, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,132
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cystic Fibrosis, Inflammatory Bowel Disease, Type 1 Diabetes, Chronic Disease Management
- Interventions
- MD2ME
- Behavioral
- Lead sponsor
- Huang, Jeannie, M.D.
- Individual
- Eligibility
- 14 Years to 22 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Hypoxic-Ischemic Encephalopathy, Hypoglycemia, Neonatal Abstinence Syndrome
- Interventions
- nfant feeding solution
- Device
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 6 Months
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Neonatal Jaundice
- Interventions
- Assessment of unbound bilirubin levels
- Other
- Lead sponsor
- Rutgers University
- Other
- Eligibility
- 6 Hours to 7 Days
- Enrollment
- 180 participants
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Pregnancy
- Interventions
- Not listed
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 48 Hours
- Enrollment
- 1,090 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1994 – 1996
- U.S. locations
- 11
- States / cities
- Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 8 more
- Conditions
- Genetic Disease, Genetic Syndrome, Genetic Predisposition to Disease, Development, Infant, Development, Child
- Interventions
- Not listed
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 4 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cystic Fibrosis
- Interventions
- VX-121/TEZ/D-IVA
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Miami, Florida • St. Petersburg, Florida
- Conditions
- Achondroplasia
- Interventions
- Infigratinib is provided as a single dose of minitablets for oral administration, Infigratinib is provided as sprinkle capsules for daily oral administration, Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration
- Drug
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Eligibility
- 0 Years to 32 Months
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 3
- States / cities
- Oakland, California • Baltimore, Maryland • Madison, Wisconsin
- Conditions
- Asthma, Eczema, Dermatitis, Atopic
- Interventions
- Not listed
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 2 Months to 7 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Bronchopulmonary Dysplasia, Very Low Birth Weight
- Interventions
- Varied albuterol dose response
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 14 Days and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Critical Illness, Pediatric Critical Illness, Respiratory Failure, Traumatic Brain Injury, Cardiac Arrest
- Interventions
- Transcranial Doppler
- Device
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 1 Day to 17 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Nicole Hamblett
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 490 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 56
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 47 more
- Conditions
- Patent Ductus Arteriosus
- Interventions
- feeding, fasting
- Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 23 Weeks to 33 Weeks
- Enrollment
- 177 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 14
- States / cities
- San Francisco, California • San Jose, California • Chicago, Illinois + 11 more
- Conditions
- Mucopolysaccharidosis II
- Interventions
- Genetic HMI-203
- Biological
- Lead sponsor
- Homology Medicines, Inc
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 5
- States / cities
- Oakland, California • New Haven, Connecticut • Hackensack, New Jersey + 2 more
- Conditions
- Cystic Fibrosis
- Interventions
- SB656933
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Minneapolis, Minnesota • Pittsburgh, Pennsylvania
- Conditions
- Cystic Fibrosis
- Interventions
- TOBI™ Podhaler™ 112 mg inhaled twice daily, Colistimethate 75 mg inhaled two times daily
- Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Prematurity
- Interventions
- Apparatuses
- Device
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- Up to 20 Minutes
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Congenital Hyperinsulinism
- Interventions
- RZ358 Sequential Group Cohort 1, RZ358 Sequential Group Cohort 2, RZ358 Sequential Group Cohort 3, RZ358 Sequential Group Cohort 4
- Drug
- Lead sponsor
- Rezolute
- Other
- Eligibility
- 2 Years to 45 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Fort Worth, Texas
- Conditions
- HELLP Syndrome (HELLP), Third Trimester, Complement Abnormality, Morbidity;Newborn, Maternal Injury, Preeclampsia Severe
- Interventions
- Eculizumab
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Cardiology, Infant Development, Development Delay
- Interventions
- NIDCAP Developmental Care
- Behavioral
- Lead sponsor
- Boston Children's Hospital
- Other
- Eligibility
- Up to 4 Months
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- GERD in Infants
- Interventions
- Omeprazole, AR formula
- Drug · Other
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 1 Day to 8 Months
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Deglutition Disorders
- Interventions
- VFSS, FEES
- Other
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 37 Weeks and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Cystic Fibrosis
- Interventions
- Not listed
- Lead sponsor
- Dayton Children's Hospital
- Other
- Eligibility
- 7 Years to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Dayton, Ohio
- Conditions
- Cystic Fibrosis
- Interventions
- Pancrelipase Delayed Release, Placebo Comparator
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 19
- States / cities
- Long Beach, California • Los Angeles, California • San Francisco, California + 16 more